Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Amgen’s Lumakras/Immunotherapy Combo Data Results Decision Due Aug 7 – $AMGN $DIA

By John F. Heerdink, Jr.

Reportedly, early trial data on Amgen Inc’s (AMGN) Lumakras was released by the World Conference on Lung Cancer (WCLC), but it has been decided that it will hold until Aug. 7 by the meeting organizers from a highly anticipated study in combination with drugs that help the immune system attack cancer.

The study will report on how well Lumakras work in combination with immunotherapies, Merck & Co’s Keytruda and Roche Holding AG’s Tecentriq were selected to be part of the press program at the organization’s Vienna meeting, informed WCLC spokesman Chris Martin.

Lumakras, an oral drug is designed to target a mutated form of a gene known as KRAS that occurs in about 13% of non-small cell lung cancers which is the most common type of lung cancer.  Last year, the U.S. Food and Drug Administration approved Lumakras for advanced lung cancer patients with KRAS mutations whose condition has worsened after chemotherapy or medicines. Amgen is focused to expand approved uses for Lumakras, including in combination with other therapies to treat people with early-stage lung cancer.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

(Read Original Story: UPDATE 1-Amgen's Lumakras/immunotherapy combo data held for August lung cancer meeting in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us